Randomized Comparison of Endothelial Progenitor Cells Capture
Stent Versus Cobalt-Chromium Stent for Treatment of
ST-Elevation Myocardial Infarction. Six-Month Clinical,
Angiographic, and IVUS Follow-Up

J 2010

Randomized Comparison of Endothelial Progenitor Cells Capture Stent Versus Cobalt-Chromium Stent for Treatment of ST-Elevation Myocardial Infarction. Six-Month Clinical, Angiographic, and IVUS Follow-Up

BYSTRON, Marián; Pavel ČERVINKA; Radim ŠPAČEK; Martin KVASNAK; Jozef JAKABČIN et al.

Základní údaje

Originální název

Randomized Comparison of Endothelial Progenitor Cells Capture Stent Versus Cobalt-Chromium Stent for Treatment of ST-Elevation Myocardial Infarction. Six-Month Clinical, Angiographic, and IVUS Follow-Up

Autoři

BYSTRON, Marián; Pavel ČERVINKA; Radim ŠPAČEK; Martin KVASNAK; Jozef JAKABČIN; Michaela ČERVINKOVÁ; Petr KALA a Petr WIDIMSKÝ

Vydání

Catheterization and Cardiovascular Intervention, 2010, 1522-1946

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.398

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00054380

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/ccd.22612

UT WoS

000283629700001

Klíčová slova anglicky

ST-elevation myocardial infarction; primary PCI; endothelial progenitor cells capture stent; stent thrombosis

Příznaky

Mezinárodní význam

Změněno: 12. 12. 2011 14:54, Mgr. Michal Petr

Anotace

V originále

The aim of this trial was to assess the feasibility and safety of endothelial progenitor cells capture (EPC) stent in the treatment of acute ST-elevation myocardial infarction (STEMI) when compared with cobalt-chromium stents (CoCr). Methods: Between July 2006 and May 2008, 100 patients with single vessel disease undergoing primary PCI for STEMI were randomly assigned to receive either EPC stent (N = 50) or CoCr stent (N = 50). High-pressure stent implantation was carried out in both groups. Dual antiplatelet treatment was administered for 30 days in both groups. All patients underwent 6-month clinical, angiographic, and IVUS follow-up. Results: The rate of major adverse cardiovascular events (MACEs) at 30 days was comparable in both groups. At 6-month follow-up, the rates of MACEs and TLR in the EPC stent group when compared with CoCr stent were 24% vs.10%; P = 0.06 and 14% vs. 4%; P = 0.08, respectively. There were three cases (6%) of stent thrombosis (ST) in the EPC stent group versus none in CoCr group. Conclusion: The use of EPC capture stents in the setting of STEMI is feasible and safe in terms of 30-days outcome. However, at the 6-month follow-up, we found a trend of higher rates of MACE and TLR in the EPC stent capture group compared to CoCr stents. The study does not support the use of EPC capture stents with short duration dual antiplatelet therapy in patients with STEMI. Future randomized studies with large sample sizes would be necessary to demonstrate the safety of such approach.

Citovat

BYSTRON, Marián; Pavel ČERVINKA; Radim ŠPAČEK; Martin KVASNAK; Jozef JAKABČIN; Michaela ČERVINKOVÁ; Petr KALA a Petr WIDIMSKÝ. Randomized Comparison of Endothelial Progenitor Cells Capture Stent Versus Cobalt-Chromium Stent for Treatment of ST-Elevation Myocardial Infarction. Six-Month Clinical, Angiographic, and IVUS Follow-Up. Catheterization and Cardiovascular Intervention. 2010, roč. 76, č. 5, s. 627-631. ISSN 1522-1946. Dostupné z: https://doi.org/10.1002/ccd.22612.

@article{962198,
   author = {Bystron, Marián and Červinka, Pavel and Špaček, Radim and Kvasnak, Martin and Jakabčin, Jozef and Červinková, Michaela and Kala, Petr and Widimský, Petr},
   article_number = {5},
   doi = {https://doi.org/10.1002/ccd.22612},
   keywords = {ST-elevation myocardial infarction; primary PCI; endothelial progenitor cells capture stent; stent thrombosis},
   language = {eng},
   issn = {1522-1946},
   journal = {Catheterization and Cardiovascular Intervention},
   title = {Randomized Comparison of Endothelial Progenitor Cells Capture Stent Versus Cobalt-Chromium Stent for Treatment of ST-Elevation Myocardial Infarction. Six-Month Clinical, Angiographic, and IVUS Follow-Up},
   volume = {76},
   year = {2010}
}

TY  - JOUR
ID  - 962198
AU  - Bystron, Marián - Červinka, Pavel - Špaček, Radim - Kvasnak, Martin - Jakabčin, Jozef - Červinková, Michaela - Kala, Petr - Widimský, Petr
PY  - 2010
TI  - Randomized Comparison of Endothelial Progenitor Cells Capture Stent Versus Cobalt-Chromium Stent for Treatment of ST-Elevation Myocardial Infarction. Six-Month Clinical, Angiographic, and IVUS Follow-Up
JF  - Catheterization and Cardiovascular Intervention
VL  - 76
IS  - 5
SP  - 627-631
EP  - 627-631
SN  - 15221946
KW  - ST-elevation myocardial infarction
KW  - primary PCI
KW  - endothelial progenitor cells capture stent
KW  - stent thrombosis
N2  - The aim of this trial was to assess the feasibility and safety of endothelial progenitor cells capture (EPC) stent in the treatment of acute ST-elevation myocardial infarction (STEMI) when compared with cobalt-chromium stents (CoCr). Methods: Between July 2006 and May 2008, 100 patients with single vessel disease undergoing primary PCI for STEMI were randomly assigned to receive either EPC stent (N = 50) or CoCr stent (N = 50). High-pressure stent implantation was carried out in both groups. Dual antiplatelet treatment was administered for 30 days in both groups. All patients underwent 6-month clinical, angiographic, and IVUS follow-up. Results: The rate of major adverse cardiovascular events (MACEs) at 30 days was comparable in both groups. At 6-month follow-up, the rates of MACEs and TLR in the EPC stent group when compared with CoCr stent were 24% vs.10%; P = 0.06 and 14% vs. 4%; P = 0.08, respectively. There were three cases (6%) of stent thrombosis (ST) in the EPC stent group versus none in CoCr group. Conclusion: The use of EPC capture stents in the setting of STEMI is feasible and safe in terms of 30-days outcome. However, at the 6-month follow-up, we found a trend of higher rates of MACE and TLR in the EPC stent capture group compared to CoCr stents. The study does not support the use of EPC capture stents with short duration dual antiplatelet therapy in patients with STEMI. Future randomized studies with large sample sizes would be necessary to demonstrate the safety of such approach.
ER  -

BYSTRON, Marián; Pavel ČERVINKA; Radim ŠPAČEK; Martin KVASNAK; Jozef JAKABČIN; Michaela ČERVINKOVÁ; Petr KALA a Petr WIDIMSKÝ. Randomized Comparison of Endothelial Progenitor Cells Capture Stent Versus Cobalt-Chromium Stent for Treatment of ST-Elevation Myocardial Infarction. Six-Month Clinical, Angiographic, and IVUS Follow-Up. \textit{Catheterization and Cardiovascular Intervention}. 2010, roč.~76, č.~5, s.~627-631. ISSN~1522-1946. Dostupné z: https://doi.org/10.1002/ccd.22612.

Přehled o publikaci